Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Parneet K, Cheema"'
Autor:
Parneet K. Cheema, Paul F. Wheatley-Price, Matthew J. Cecchini, Peter M. Ellis, Alexander V. Louie, Sara Moore, Brandon S. Sheffield, Jonathan D. Spicer, Patrick James Villeneuve, Natasha B. Leighl
Publikováno v:
Current Oncology, Vol 31, Iss 11, Pp 6979-6999 (2024)
Therapeutic strategies for early-stage non-small cell lung cancer (NSCLC) are advancing, with immune checkpoint inhibitors (ICIs) and targeted therapies making their way into neoadjuvant and adjuvant settings. With recent advances, there was a need f
Externí odkaz:
https://doaj.org/article/234336a74a674bd18fa75f41a4f0977a
Autor:
Parneet K. Cheema, Iqra Syed, Femida Gwadry-Sridhar, Muhammad Rakibuz-Zaman, Robin Sachdeva, Alec Pencz, Luna Zhan, Katrina Hueniken, Devalben Patel, Karmugi Balaratnam, Khaleeq Khan, Benjamin Grant, Brandon S. Sheffield, M. Elizabeth O. Locke, Daniel Moldaver, Mary Kate Shanahan, Geoffrey Liu, M. Sara Kuruvilla
Publikováno v:
Current Oncology, Vol 31, Iss 11, Pp 6735-6748 (2024)
Treatment options for non-small cell lung cancer (NSCLC) are evolving, given recent and expected approvals of immune checkpoint inhibitors (ICIs) targeting programmed cell death-(ligand) 1 (PD-1/PD-L1). We retrospectively evaluated outcomes among pat
Externí odkaz:
https://doaj.org/article/c3ea523b419841c58d6a36f878ba5e1b
Autor:
Parneet K. Cheema, Marco A. J. Iafolla, Husam Abdel-Qadir, Andrew B. Bellini, Nazira Chatur, Natasha Chandok, Vikram R. Comondore, Morven Cunningham, Ilana Halperin, Anne B. Hu, Diana Jaskolka, Saeed Darvish-Kazem, Masud H. Khandaker, Abhijat Kitchlu, Jasdip S. Sachdeva, Shane Shapera, Nicholas R. J. Woolnough, Massey Nematollahi
Publikováno v:
Current Oncology, Vol 31, Iss 10, Pp 6356-6383 (2024)
The increased use of immune checkpoint inhibitors (ICIs) across cancer programs has created the need for standardized monitoring and management of immune-related adverse events (irAEs). Delayed recognition without appropriate treatment can have serio
Externí odkaz:
https://doaj.org/article/3e38519628c5425cabe1255ed3c8d53e
Autor:
Parneet K. Cheema, Shantanu O. Banerji, Normand Blais, Quincy S.-C. Chu, Rosalyn A. Juergens, Natasha B. Leighl, Adrian Sacher, Brandon S. Sheffield, Stephanie Snow, Mark Vincent, Paul F. Wheatley-Price, Stephen Yip, Barbara L. Melosky
Publikováno v:
Current Oncology, Vol 30, Iss 7, Pp 6473-6496 (2023)
Activating mutations in Kirsten rat sarcoma viral oncogene homologue (KRAS), in particular, a point mutation leading to a glycine-to-cysteine substitution at codon 12 (G12C), are among the most frequent genomic alterations in non-small cell lung canc
Externí odkaz:
https://doaj.org/article/ab0cb512b2d24cbeafaef622627ed0b6
Autor:
Barbara L. Melosky, Natasha B. Leighl, David Dawe, Normand Blais, Paul F. Wheatley-Price, Quincy S.-C. Chu, Rosalyn A. Juergens, Peter M. Ellis, Alexander Sun, Devin Schellenberg, Diana N. Ionescu, Parneet K. Cheema
Publikováno v:
Current Oncology, Vol 30, Iss 7, Pp 6289-6315 (2023)
Small-cell lung cancer (SCLC) is an aggressive, neuroendocrine tumour with high relapse rates, and significant morbidity and mortality. Apart from advances in radiation therapy, progress in the systemic treatment of SCLC had been stagnant for over th
Externí odkaz:
https://doaj.org/article/4018347cac8e41ddb2d0bdfcb844469e
Autor:
Hye Ryun Kim, MD, PhD, Mark M. Awad, MD, PhD, Alejandro Navarro, MD, Maya Gottfried, MD, Solange Peters, MD, PhD, Tibor Csőszi, MD, Parneet K. Cheema, MD, Delvys Rodriguez-Abreu, MD, PhD, Mirjana Wollner, MD, James Chih-Hsin Yang, MD, PhD, Julien Mazieres, MD, PhD, Francisco J. Orlandi, MD, Alexander Luft, MD, PhD, Mahmut Gümüş, MD, Terufumi Kato, MD, Gregory P. Kalemkerian, MD, Yiwen Luo, PhD, Melissa L. Santorelli, PhD, MPH, M. Catherine Pietanza, MD, Charles M. Rudin, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 11, Pp 100572- (2023)
Introduction: In the phase 3 KEYNOTE-604 study (NCT03066778), pembrolizumab plus etoposide and platinum chemotherapy (EP) significantly (p = 0.0023) improved progression-free survival versus placebo plus EP in previously untreated extensive-stage SCL
Externí odkaz:
https://doaj.org/article/0e1816cce869459686df7d5b2f6d1a2d
Autor:
Diana N. Ionescu, Tracy L. Stockley, Shantanu Banerji, Christian Couture, Cheryl A. Mather, Zhaolin Xu, Normand Blais, Parneet K. Cheema, Quincy S.-C. Chu, Barbara Melosky, Natasha B. Leighl
Publikováno v:
Current Oncology, Vol 29, Iss 7, Pp 4981-4997 (2022)
Non-small cell lung cancer (NSCLC) has historically been associated with a poor prognosis and low 5-year survival, but the use of targeted therapies in NSCLC has improved patient outcomes over the past 10 years. The pace of development of new targete
Externí odkaz:
https://doaj.org/article/1ed9d430c59d4d3496913a7bcdcbbc84
Autor:
Parneet K. Cheema, Marco A. J. Iafolla, Massey Nematollahi, FeRevelyn Berco, Deepanjali Kaushik, Priscilla Matthews, William R. Raskin, Kirstin A. Perdrizet, Shaan Dudani, Juhi Husain, Margaret Balcewicz, Philip G. Kuruvilla, Stephen M. Reingold, Henry J. Conter
Publikováno v:
Current Oncology, Vol 29, Iss 2, Pp 869-880 (2022)
The increased use of immune checkpoint inhibitors across cancer programs has created the need for standardized patient assessment, education, monitoring, and management of immune-related adverse events (irAEs). At William Osler Health System in Bramp
Externí odkaz:
https://doaj.org/article/a6006115821a4207b3e6e19870a4a5d7
Autor:
Brandon S. Sheffield, Andrea Beharry, Joanne Diep, Kirstin Perdrizet, Marco A. J. Iafolla, William Raskin, Shaan Dudani, Mary Anne Brett, Blerta Starova, Brian Olsen, Parneet K. Cheema
Publikováno v:
Current Oncology, Vol 29, Iss 3, Pp 1326-1334 (2022)
Purpose: Biomarker data are critical to the delivery of precision cancer care. The average turnaround of next-generation sequencing (NGS) reports is over 2 weeks, and in-house availability is typically limited to academic centers. Lengthy turnaround
Externí odkaz:
https://doaj.org/article/52d2618297474676ad438d2b00ac7538
Autor:
Michael C. Tjong, Malavan Ragulojan, Ian Poon, Alexander V. Louie, Susanna Y. Cheng, Mark Doherty, Liying Zhang, Yee Ung, Patrick Cheung, Parneet K. Cheema
Publikováno v:
Current Oncology, Vol 29, Iss 1, Pp 221-230 (2022)
Background: The safety impact of radiotherapy (RT) timing relative to immune checkpoint inhibitors (ICIs) for advanced non-small-cell lung cancer (NSCLC) is unclear. We investigated if RT within 14 days (Interval 1) and 90 days (Interval 2) of ICI us
Externí odkaz:
https://doaj.org/article/0edf7c18457b4be1af3cf8d0a7cec179